Pfizer is a growth-and-income stock found in many retirement portfolios. But is the competition from biotech "disruptors" getting too hot for this Big Pharma stalwart? Read More

As the largest health insurer in the U.S., UnitedHealth Group is poised to greatly benefit from booming health care expenditures. But do proposed government policy changes threaten the stock? Read More

Health services giant Johnson & Johnson has been a reliable growth-and-income stock for years, but can it overcome the scandal about its allegedly carcinogenic talcum powder? Read More

Cash-rich tech titans such as Microsoft have become growth-and-income plays. But as headwinds mount for the tech sector, how safe is the firm's dividend? Read More

BP is a high-yielding stock prized by investors who seek steady income. But amid the prolonged volatility of oil and gas prices, can this energy "super major" sustain its dividend? Read More

Apple has racked up phenomenal capital appreciation over the years, but many investors underappreciate its dividend growth potential. Here's why Apple is an income generator, too. Read More

Verizon is one of the largest communication technology companies in the world, with a stock that offers robust income. But is the high dividend sustainable amid growing telecom competition? Read More

Legendary carmaker Ford is pivoting to new technologies to stay competitive. The stock's high dividend is attracting income investors, but is the payout a dividend trap? Read More

As economic recovery enters the "late stage," consumer staples stocks such as Procter & Gamble should rise. But is the dividend appealing too? Read More

Retailing icon Walmart is a "Dividend Aristocrat" that has consistently boosted its dividend, but does the e-commerce onslaught pose a threat to the payout? Read More